Singapore, July 1, 2022 - Credo Diagnostics is pleased to announce our participation at the coming 2022 AACC Annual Scientific Meeting & Clinical Lab Expo event from July 26 - 28, 2022 in Chicago, IL, USA.
The AACC Annual Scientific Meeting & Clinical Lab Expo is the world’s leading global professional gathering for clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine. It will showcase the cutting-edge science and technology changing the future of laboratory medicine.
At the 2019 AACC in Anaheim, CA, Booth #4339, Credo Diagnostics launched the VitaPCR™ Instrument and the first VitaPCR™ Influenza A&B Assay.
Today, Credo Diagnostics’ product lines include the VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Influenza/SARS-CoV-2 Assay, VitaPCR™ Influenza/RSV Assay, and VitaPCR™ Strep A Assay.
For the coming 2022 AACC in Chicago, Credo Diagnostics are happy to announce our participation, and importantly, Credo Diagnostics will reveal the arrival of an exciting new platform and a whole series of new Assays.
“Today, it is a great honour to see our solutions accepted and requested by users around the world. We strive to continually provide the best solutions to our customers, and we will never stop innovating." said Dr. Wong Jr. Winston, Chairman, and CEO of Credo Diagnostics Biomedical.
Come visit Credo Diagnostics at Booth #4456 to see for yourself.
Credo Diagnostics, “Advanced Medical Technology For All”
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.